Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pheochromocytoma 1Neoplasms 1Neoplasm Metastasis 1

Interventions

3-Iodobenzylguanidine 5Doxorubicin 3cabozantinib 2Temozolomide 2Radiotherapy 2Phenoxybenzamine 2Ifosfamide 2Filgrastim 2Everolimus 2Doxazosin 2Dexmedetomidine 2vatalanib 1temsirolimus 1pegfilgrastim 1lenvatinib 1fostamatinib 1atezolizumab 1anlotinib 1Vinorelbine 1Tamoxifen 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Saline Solution 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pheochromocytoma × 6-fluorodopamine × Clear all
NCT00028106 2017-07-02

131MIBG to Treat Malignant Pheochromocytoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
32 enrolled
Endocrine

Neoplasm Metastasis, Neoplasms, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡